Search Articles for 'Angioblast Systems'- HEART RESULTS SHOW PROMISE FOR MESOBLAST
MESOBLAST says the three-month interim results of the company’s Phase 2 clinical trial of its stem cell treatment for congestive heart failure show the product leads to significantly improved heart muscle function in patients.
News [5/17/2009]
Revascor, Damaged heart muscle, Improved ejection fraction, Mesoblast, Mesoblast United States-based associated company, Angioblast Systems, Moderate-severe congestive heart failure, Echocardiogram, Lowest dose of Revascor, Professor Silviu Itescu, Monash University Centre of Cardiovascular Research and Education in Therapeutics, Professor Henry Krum, Chronic heart failure
 |
|
